Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Regeneron

States Challenge 23andMe Over Genetic Data Sale in Bankruptcy Deal

States sue to halt Regeneron's 23andMe acquisition, citing privacy concerns over user DNA data, as a court-ordered report on the deal's impact looms.

International Business Times

23andMe back on the auction block after former CEO makes 11th-hour bid

23andMe back on the auction block after former CEO makes 11th-hour bid

Anne Wojcicki, ex-CEO of the DNA testing firm, put in a $305m bid, upending Regeneron’s $256m agreement

The Guardian - US

Regeneron Pharmaceuticals Stock: Is Wall Street Bullish or Bearish?

Regeneron Pharmaceuticals Stock: Is Wall Street Bullish or Bearish?

Despite Regeneron Pharmaceuticals' underperformance relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

23andMe Sells DNA Database to Regeneron in £256m Deal: Is Your Data Safe?

23andMe's sale to Regeneron transfers genetic data for drug development, raising privacy issues and concerns over consumer control and benefits.

International Business Times UK

Trump the AI salesman makes deals in the Gulf – and rich men benefit

The president sold the US model of the industry that made it: enormous power concentrated in the hands of a few men

The Guardian - US

Bankrupt DNA testing firm 23andMe to be purchased for $256m

Drugmaker Regeneron Pharmaceuticals’ capture of genetic testing firm in bankruptcy auction raises privacy concerns

The Guardian - US

Biotechnology company Regeneron buying 23andMe for $256 million

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection

The Independent UK

inkl

Read news from The Economist, FT, and more,
with one subscription

Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025

Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025

CCOI, AESI, and REGN are near one-year lows but remain favored by analysts; watch these stocks for future growth potential.

Best Biotech Stocks to Buy in 2025

Best Biotech Stocks to Buy in 2025

Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.

3 Stocks With Ironclad Balance Sheets for Long-Term Stability

3 Stocks With Ironclad Balance Sheets for Long-Term Stability

Check out these three stocks with balance sheets that have a case for being among the strongest in the entire stock market.

Regeneron: Is It the Perfect Biotech Stock for Value and Growth?

Regeneron: Is It the Perfect Biotech Stock for Value and Growth?

Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.

Regeneron Pharmaceuticals Stock: Analyst Estimates & Ratings

Regeneron Pharmaceuticals Stock: Analyst Estimates & Ratings

Despite Regeneron Pharmaceuticals’ underperformance relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.

Billions in Buybacks: 4 Stocks Rewarding Shareholders Now

Billions in Buybacks: 4 Stocks Rewarding Shareholders Now

These stocks are looking to return varying amounts of capital to shareholders using buybacks. One fintech's buyback capacity is equal to 25% of its market cap.

Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers

Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers

The Fortune 500 pharma giant will sequence the exomes of 10 million people, with the goal of developing new therapies and more.

Get all your
news in one place.

100's of premium titles.
One news app.

3 S&P 500 Stocks to Buy in 2025 With Big Rebound Potential

As markets rise, a handful of resilient stocks that were bruised could rebound over 30%, powered by strong fundamentals and bullish prospects.

3 Nasdaq-100 Stocks With 25% to 53% Upside Potential

These three Nasdaq-100 Stocks shine as prime opportunities as analysts forecast 25% to 53% upside potential.

Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Despite Regeneron Pharmaceuticals’ significant underperformance relative to Nasdaq recently, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Regeneron Pharmaceuticals Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN).

Get all your
news in one place.

100's of premium titles.
One news app.

Intellia's Single-Dose Gene Editing Treatment for ATTR Amyloidosis Gets FDA Fast-Track Approval Boost

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA)

Here's What to Expect From Regeneron Pharmaceuticals’ Next Earnings Report

Regeneron Pharmaceuticals is expected to report its fiscal third-quarter earnings this month, and analysts project a single-digit profit plunge.

Is Regeneron Pharmaceuticals Stock Outperforming the S&P 500?

Regeneron Pharmaceuticals has outperformed the broader S&P 500 Index over the past year, and Wall Street analysts remain bullish on the stock’s prospects.

Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and Wall Street analysts remain bullish on the stock’s prospects.

Earnings Preview: What to Expect From Regeneron Pharmaceuticals' Report

Regeneron Pharmaceuticals is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit increase.

How Is Regeneron Pharmaceuticals' Stock Performance Compared to Other Biotechnology Stocks?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and Wall Street analysts are optimistic about the stock’s outlook.

Regeneron To Defend Against DOJ Complaint On Drug Pricing

Regeneron faces DOJ legal challenge over drug-price manipulation allegations, vows to defend itself. Case could impact pharmaceutical industry and drug pri...

1 2 3 4

People

207,247 stories

Nvidia Jensen Huang

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Arista Networks

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

406,527 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play